Arrowhead Pharmaceuticals (ARWR) Other Non Operating Income (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Other Non Operating Income of -$1.6 million for Q1 2026, down 680.87% on a QoQ basis from $277000.0 in Q4 2025, and down 467.35% year-over-year from $438000.0 in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Other Non Operating Income (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Other Non Operating Income history runs 16 years deep, the most recent figure standing at -$1.6 million for Q1 2026.
- Quarterly Other Non Operating Income fell 467.35% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 299.37% YoY) and the FY2025 annual result came in at $5.3 million, up 400.86% from the prior year.
- Other Non Operating Income was -$1.6 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $277000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $4.7 million in Q3 2025 and bottomed at -$3.1 million in Q3 2024.
- A 5-year average of $305235.3 and a median of $306000.0 in 2023 frame the typical range for Other Non Operating Income.
- Peak annual rise in Other Non Operating Income reached 2262.5% in 2024, while the deepest fall reached 534.87% in 2024.
- Arrowhead Pharmaceuticals' Other Non Operating Income stood at $507000.0 in 2022, then slipped by 16.96% to $421000.0 in 2023, then dropped by 19.0% to $341000.0 in 2024, then dropped by 18.77% to $277000.0 in 2025, then slumped by 680.87% to -$1.6 million in 2026.
- Business Quant data shows ARWR's Other Non Operating Income at -$1.6 million in Q1 2026, $277000.0 in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.61 Mn |
| Dec 31, 2025 | 277,000.00 |
| Sep 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | -176,000.00 |
| Mar 31, 2025 | 438,000.00 |
| Dec 31, 2024 | 341,000.00 |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | 760,000.00 |
| Mar 31, 2024 | 189,000.00 |
| Dec 31, 2023 | 421,000.00 |
| Sep 30, 2023 | 717,000.00 |
| Jun 30, 2023 | 306,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 507,000.00 |
| Sep 30, 2022 | 90,000.00 |
| Jun 30, 2022 | -377,000.00 |
| Mar 31, 2022 | 1.76 Mn |
| Dec 31, 2021 | -707,000.00 |
| Sep 30, 2021 | 363,000.00 |
| Jun 30, 2021 | 664,000.00 |